The AAV vector manufacturing market is mainly fueled by the expanding landscape of gene therapy research and development, as AAV vectors are extensively utilized for therapeutic gene delivery because ...

New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...

The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and ...

The "Adeno-Associated Virus (AAV) Vectors in Gene Therapy – Market Insight, Epidemiology and Market Forecast – 2030" drug pipelines has been added to ResearchAndMarkets.com’s offering. This report ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...

The "Adeno-Associated Virus (AAV) Vectors in Gene Therapy – Epidemiology Insight – 2030" report has been added to ResearchAndMarkets.com’s offering. This ‘Adeno-Associated Virus (AAV) Vector Based ...

Conjugation of universal, functionally de-targeted OneAAVTM capsid provides on-demand specificity and scalabilityto address ...

In a recent review published in Signal Transduction and Targeted Therapy, researchers presented recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases. Study: ...

Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the “Company"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with ...